Vertex Pharmaceuticals (VRTX) Debt/Assets Ratio: History & Chart

Vertex Pharmaceuticals Incorporated(VRTX)

Biotechnology · Boston, MA

$521.12-7.78 (-1.47%)

Delayed quote: Sep 9, 2026, 4:00 PM EDT

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA

6,400 employees

www.vrtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Reshma Kewalramani

View full financials

VRTX Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

7.21%

DEBT TO ASSETS RATIO AVG TTM

8.66%

DEBT TO ASSETS RATIO AVG 3Y

5.79%

DEBT TO ASSETS RATIO AVG 5Y

5.83%

DEBT TO ASSETS RATIO AVG 10Y

8.40%

DEBT TO ASSETS RATIO AVG 15Y

15.33%

DEBT TO ASSETS RATIO AVG 20Y

15.86%

CURRENT VS TTM AVG

-16.72%

CURRENT VS 3Y AVG

+24.54%

CURRENT VS 5Y AVG

+23.74%

CURRENT VS 10Y AVG

-14.14%

CURRENT VS 15Y AVG

-52.96%

CURRENT VS 20Y AVG

-54.55%

SECTOR MEDIAN · HEALTHCARE

0.29%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+2430.31%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Vertex Pharmaceuticals Incorporated (VRTX)	$132.26B	7.21%	8.66%	5.79%	5.83%
Bristol-Myers Squibb Company (BMY)vs ›	$131.57B	0.49%	N/A	N/A	N/A
Intuitive Surgical, Inc. (ISRG)vs ›	$124.79B	0.00%	N/A	N/A	N/A
CVS Health Corp. (CVS)vs ›	$121.70B	0.30%	N/A	N/A	N/A
Danaher Corporation (DHR)vs ›	$144.11B	0.29%	N/A	N/A	N/A
Medtronic plc (MDT)vs ›	$117.62B	0.30%	N/A	N/A	N/A
Pfizer Inc. (PFE)vs ›	$158.33B	0.31%	N/A	N/A	N/A
Stryker Corporation (SYK)vs ›	$105.57B	0.31%	N/A	N/A	N/A
McKesson Corporation (MCK)vs ›	$104.40B	0.13%	N/A	N/A	N/A
Sanofi (SNY)vs ›	$102.89B	0.18%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Vertex Pharmaceuticals Incorporated (VRTX)

$132.26B

7.21%

8.66%

5.79%

5.83%

Bristol-Myers Squibb Company (BMY)vs ›

$131.57B

0.49%

N/A

Intuitive Surgical, Inc. (ISRG)vs ›

$124.79B

0.00%

N/A

CVS Health Corp. (CVS)vs ›

$121.70B

0.30%

N/A

Danaher Corporation (DHR)vs ›

$144.11B

0.29%

N/A

Medtronic plc (MDT)vs ›

$117.62B

0.30%

N/A

Pfizer Inc. (PFE)vs ›

$158.33B

0.31%

N/A

Stryker Corporation (SYK)vs ›

$105.57B

0.31%

N/A

McKesson Corporation (MCK)vs ›

$104.40B

0.13%

N/A

Sanofi (SNY)vs ›

$102.89B

0.18%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The debt to assets ratio for VRTX stock is 7.21%.

Is Vertex Pharmaceuticals Incorporated's debt to assets ratio high or low?

The debt to assets ratio of 7.21% is 24% above its 5-year average of 5.83%, around the middle of its 5-year range (3.02%–14.85%).

What is the TTM average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The TTM average debt to assets ratio for VRTX stock is 8.66%.

What is the 3Y average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 3Y average debt to assets ratio for VRTX stock is 5.79%.

What is the 5Y average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 5Y average debt to assets ratio for VRTX stock is 5.83%.

What is the 10Y average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 10Y average debt to assets ratio for VRTX stock is 8.40%.

What is the 15Y average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 15Y average debt to assets ratio for VRTX stock is 15.33%.

What is the 20Y average debt to assets ratio for Vertex Pharmaceuticals Incorporated (VRTX)?

The 20Y average debt to assets ratio for VRTX stock is 15.86%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	7.21%
2026-03-31	7.50%
2025-12-31	14.85%
2025-09-30	7.38%
2025-06-30	6.35%
2025-03-31	7.21%
2024-12-31	7.76%
2024-09-30	7.66%
2024-06-30	4.64%
2024-03-31	3.02%
2023-12-31	3.56%
2023-09-30	3.43%
2023-06-30	3.77%
2023-03-31	4.16%
2022-12-31	4.96%
2022-09-30	4.94%
2022-06-30	5.44%
2022-03-31	6.12%
2021-12-31	7.20%
2021-09-30	6.95%
2021-06-30	7.31%
2021-03-31	7.42%
2020-12-31	7.93%
2020-09-30	4.84%
2020-06-30	5.11%
2020-03-31	5.99%
2019-12-31	7.95%
2019-09-30	8.04%
2019-06-30	8.70%
2019-03-31	9.53%
2018-12-31	9.40%
2018-09-30	12.73%
2018-06-30	13.67%
2018-03-31	15.06%
2017-12-31	17.10%
2017-09-30	18.36%
2017-06-30	17.30%
2017-03-31	18.61%
2016-12-31	29.05%
2016-09-30	31.49%
2016-06-30	32.19%
2016-03-31	33.14%
2015-12-31	33.09%
2015-09-30	33.73%
2015-06-30	34.73%
2015-03-31	38.50%
2014-12-31	35.31%
2014-09-30	34.42%
2014-06-30	25.40%
2014-03-31	24.63%
2013-12-31	21.84%
2013-09-30	17.28%
2013-06-30	15.39%
2013-03-31	30.93%
2012-12-31	25.26%
2012-09-30	14.71%
2012-06-30	15.36%
2012-03-31	17.05%
2011-12-31	20.68%
2011-09-30	23.82%
2011-06-30	28.06%
2011-03-31	31.99%
2010-12-31	31.12%
2010-09-30	25.80%
2010-06-30	5.22%
2010-03-31	7.08%
2009-12-31	9.51%
2009-09-30	16.70%
2009-06-30	10.00%
2009-03-31	18.36%
2008-12-31	29.32%
2008-09-30	26.93%
2008-06-30	29.61%
2008-03-31	32.32%
2007-12-31	3.32%
2007-09-30	3.05%
2007-06-30	8.16%
2007-03-31	7.81%
2006-12-31	13.43%
2006-09-30	11.28%
2006-06-30	28.79%
2006-03-31	34.33%
2005-12-31	32.80%
2005-09-30	53.50%
2005-06-30	56.12%
2005-03-31	69.18%
2004-12-31	61.42%
2004-09-30	55.66%
2004-06-30	51.70%
2004-03-31	47.08%
2003-12-31	50.23%
2003-09-30	46.50%
2003-06-30	43.28%
2003-03-31	39.26%
2002-12-31	40.23%
2002-09-30	39.02%

DATE

DEBT TO ASSETS RATIO

2026-06-30

7.21%

2026-03-31

7.50%

2025-12-31

14.85%

2025-09-30

7.38%

2025-06-30

6.35%

2025-03-31

7.21%

2024-12-31

7.76%

2024-09-30

7.66%

2024-06-30

4.64%

2024-03-31

3.02%

2023-12-31

3.56%

2023-09-30

3.43%

2023-06-30

3.77%

2023-03-31

4.16%

2022-12-31

4.96%

2022-09-30

4.94%

2022-06-30

5.44%

2022-03-31

6.12%

2021-12-31

7.20%

2021-09-30

6.95%

2021-06-30

7.31%

2021-03-31

7.42%

2020-12-31

7.93%

2020-09-30

4.84%

2020-06-30

5.11%

2020-03-31

5.99%

2019-12-31

7.95%

2019-09-30

8.04%

2019-06-30

8.70%

2019-03-31

9.53%

2018-12-31

9.40%

2018-09-30

12.73%

2018-06-30

13.67%

2018-03-31

15.06%

2017-12-31

17.10%

2017-09-30

18.36%

2017-06-30

17.30%

2017-03-31

18.61%

2016-12-31

29.05%

2016-09-30

31.49%

2016-06-30

32.19%

2016-03-31

33.14%

2015-12-31

33.09%

2015-09-30

33.73%

2015-06-30

34.73%

2015-03-31

38.50%

2014-12-31

35.31%

2014-09-30

34.42%

2014-06-30

25.40%

2014-03-31

24.63%

2013-12-31

21.84%

2013-09-30

17.28%

2013-06-30

15.39%

2013-03-31

30.93%

2012-12-31

25.26%

2012-09-30

14.71%

2012-06-30

15.36%

2012-03-31

17.05%

2011-12-31

20.68%

2011-09-30

23.82%

2011-06-30

28.06%

2011-03-31

31.99%

2010-12-31

31.12%

2010-09-30

25.80%

2010-06-30

5.22%

2010-03-31

7.08%

2009-12-31

9.51%

2009-09-30

16.70%

2009-06-30

10.00%

2009-03-31

18.36%

2008-12-31

29.32%

2008-09-30

26.93%

2008-06-30

29.61%

2008-03-31

32.32%

2007-12-31

3.32%

2007-09-30

3.05%

2007-06-30

8.16%

2007-03-31

7.81%

2006-12-31

13.43%

2006-09-30

11.28%

2006-06-30

28.79%

2006-03-31

34.33%

2005-12-31

32.80%

2005-09-30

53.50%

2005-06-30

56.12%

2005-03-31

69.18%

2004-12-31

61.42%

2004-09-30

55.66%

2004-06-30

51.70%

2004-03-31

47.08%

2003-12-31

50.23%

2003-09-30

46.50%

2003-06-30

43.28%

2003-03-31

39.26%

2002-12-31

40.23%

2002-09-30

39.02%

Debt to Assets Ratio: 7.21%

VRTX Debt to Assets Ratio

VRTX Average Debt to Assets Ratio Chart

VRTX Current vs Average Debt to Assets Ratio Chart

VRTX Debt to Assets Ratio Metrics

VRTX Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

VRTX Debt to Assets Ratio History

Related Metrics